Healthy volunteers needed to test new drug for rare eye disease

NCT ID NCT07417566

Recruiting now Knowledge-focused Sponsor: Heronova Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 12 times

Summary

This early-stage study tests the safety and how the body processes an experimental oral drug called DC6001 in 76 healthy adults aged 18-55. The drug is being developed for Stargardt disease, a rare inherited eye condition that causes vision loss. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood. This study does not offer treatment benefits but is essential for determining safe doses for future trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tongren Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

STARGARDT DISEASE